ZG006
Phase 3Small molecule
ZG006 is one of 154 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
5
Indications
10
Total Trials
10
Active Trials
153
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Verzenio
Eli LillyPhase 3
Provenge
PProstate Oncology Specialists, Inc.
Phase 3
ZG006
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Docetaxel /m²
AstraZenecaPhase 3
Pasritamig
Johnson & JohnsonPhase 3
Fuzuloparib
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer3 trials
Neuroendocrine Carcinoma3 trials
Lung Cancer1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ZG006. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details